MediGene AG · LS:A40ESG
MediGene — Q1 2015 Earnings Presentation
17 slides from MediGene's earnings presentation, May 12, 2015
Slide 1: Analyst Conference Call: Results for the first 3 months of 2015
ANALYST CONFERENCE CALL Results for the first 3 months of 2015 Dr. Frank Mathias, CEO Peter Llewellyn-Davies, CFO Prof. Dolores J. Schendel, CSO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: Major events since the beginning of 2015
Major events since the beginning of 2015 Phase I/II trial with DC vaccines in AML initiated Licenced EU patent for the process to manufacture DC vaccines granted Early clinical data on DC vaccines presented at AACR Congress by academic partner Oslo University Publication on TCRs in “Nature Biotechno
Slide 4: Financial Report Q1 2015
medigene Financial Report Q1 2015
Slide 5: Financial overview for the first 3 months of 2015
Financial overview for the first 3 months of 2015 Royalties from Veregen® increased by 39% to €589 k (Q1 2014: €423 k) Total revenue decreased by 31% to €1,686 k (Q1 2014: €2,430 k) due to One-off milestone payment for Veregen® in Q1-2014 R&D expenses for immunotherapy programmes significantly incre
Slide 6: Increase in Veregen royalties
Increase in Veregen® royalties In € m Veregen® In-market sales Total Veregen® revenue Total revenue +35% 3.9 2.9 2.4 1.3 -31% 1.7 -46% 0.7 3M 2014 3M 2015 3M 2014 3M 2015 3M 2014 3M 2015 Revenue (in € k) Q1 2014 Q1 2015 Change Veregen® Royalties 423 589 39% Product revenue (supply 226 125 -45% chain
Slide 7: Operating expenses as planned - Significant investments in immunotherapies
Operating expenses as planned - Significant investments in immunotherapies In € m R&D expenses SG&A expenses +21% 2.2 -21% 1.6 1.9 1.7 3M 2014 3M 2015 3M 2014 3M 2015 R&D expenses: SG&A expenses: Increase due to planned Lower costs due to Trianta acquisition expenses in immunotherapies expenses in 2
Slide 8: Planned increase in EBITDA loss
Planned increase in EBITDA loss In € m EBITDA 3-Months net result -1.5 +41% -2.0 +80% -2.0 -3.7 3M 2014 3M 2015 3M 2014 3M 2015 Increase in EBITDA loss due to lower revenues and higher expenses Increase in net loss due to Cowen currency book revaluation by € 1.5 m 8
Slide 9: On track with financial guidance 2015
On track with financial guidance 2015 2014 Guidance 2015 Double digit percentage Veregen® royalties €2.4 m increase Veregen® total revenue €5.2 m stable R&D expenses €2.9 m €7-9 m Immunotherapies EBITDA loss €2.1 m €11-13 m Total revenue consists mainly of Revenue Veregen® Income from R&D fund
Slide 10: Current shareholder structure
Current shareholder structure* 10,1% 5,5% 4,4% Aviva SynCore 5,0% DJS Montana Ridgeback 6,3% Morgan Stanley RTW Master Fund Freefloat ** (< 3%) 3,9% 64,8% Key share information • 13.9 m shares outstanding • 11.9 m authorized capital *based on last voting right notifications **Shareholding below 3% 1
Slide 11: Ownership structure by type of investor
Ownership structure by type of investor SMB and End 2014 EMB; 4,6% Q1 2015 SMB and EMB; 4,7% Private Private Investors; Investors; <42% 49% Institutional Institutional Investors; Investors; 46% 54% Institutional and international investors increased to 54% (Dec 2014: 49%) Private investors reduced t
Slide 12: Focus immunotherapies - Outlook
Focus immunotherapies - Outlook
Slide 13: Pipeline focus – innovative immunotherapies in preclinical and clinical development
Pipeline focus – innovative immunotherapies in preclinical and clinical development PROJECT INDICATION PRECLINICAL PHASE I PHASE II PHASE III APPROVAL MARKET DC vaccine Prostate cancer* DC vaccine AML** DC vaccine AML TCRs Cancer Leukaemia and TABs autoimmune d. * investigator initiated trial (IIT)
Slide 14: Outlook for immunotherapy platforms
Outlook for immunotherapy platforms DCs Outlook: Convincing therapeutic data in patients vaccinated for more than 1.5 years Continue investigator-initiated trials and compassionate use programme Conduct the company-sponsored phase I/II study in AML TCRs Outlook: Demonstration on development of TCRs
Slide 15: inspired by immunotherapies
b “ —_ fF . inspired by therapies immuno
Slide 16: Questions & Answers
medigene Questions & Answers
Slide 17: Medigene AG contact details
Medigene AG MediGene AG T +49 - 89 - 20 00 33 - 0 Lochhamer Straße 11 F +49 - 89 - 20 00 33 - 2920 82152 Planegg/Martinsried Planegg / Martinsried investor@medigene.com Germany www.medigene.com Listed on Frankfurt Stock Exchange (MDG1, (MDG, Prime PrimeStandard) Standard)